home / stock / gray / gray news

GRAY News and Press, Graybug Vision Inc. From 11/15/21

Stock Information
Company Name: Graybug Vision Inc.
Stock Symbol: GRAY
Market: NASDAQ
Menu
GRAY GRAY Quote GRAY Short GRAY News GRAY Articles GRAY Message Board
Get GRAY Alerts

News, Short Squeeze, Breakout and More Instantly...
GRAY - Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

BALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive...
GRAY - Graybug Vision EPS misses by $0.01

Graybug Vision (NASDAQ:GRAY): Q3 GAAP EPS of -$0.38 misses by $0.01. Revenue of $0M Press Release For further details see: Graybug Vision EPS misses by $0.01

GRAY - Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2021, and Recent Corporate Developments

BALTIMORE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate developments ...

GRAY - Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting

BALTIMORE, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced two clinical data presentations at the Ame...
GRAY - Graybug Vision to Participate in the Annual Ophthalmology Innovation Summit (OIS) Retina@ASRS Conference

BALTIMORE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executiv...

GRAY - Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMD

55% of GB-102 1mg patients in Extension Study experienced duration of 12+ months, while maintaining their visual acuity and central retinal thickness 73% reduction of injection burden for patients participating in Extension Study GB-102 1mg ...

GRAY - Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference

BALTIMORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executiv...
GRAY - Enveric Biosciences and Cellect Biotechnology among healthcare gainers; Forte Biosciences among losers

Gainers: Cellect Biotechnology (NASDAQ:APOP) +39%. NeuroOne Medical Technologies (NASDAQ:NMTC) +17%. Enveric Biosciences (NASDAQ:ENVB) +16%. Impel NeuroPharma (NASDAQ:IMPL) +12%. Progenity (NASDAQ:PROG) +10%. Losers: Forte Biosciences (NASDAQ:FBRX) -81%. Evelo Biosciences (NASDAQ:EV...

GRAY - Graybug Vision Announces Financial Results for the Three and Six Months Ended June 30, 2021, and Recent Corporate Developments

REDWOOD CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate de...

GRAY - Graybug Vision to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference

REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chie...
Previous 10 Next 10